AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (600.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake

Andrew Feslerc, Ga-Ram Hwanga, Jingfang Jua,b( )
Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
The Northport Veteran’s Administration Medical Center, Northport, NY 11768, USA
Curamir Therapeutics Inc., Woburn, MA 01801, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 11 Issue 1,
January 2024
Pages 23-25
DOI: 10.1016/j.gendis.2022.11.020

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Fesler A, Hwang G-R, Ju J. Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake. Genes & Diseases, 2024, 11(1): 23-25. https://doi.org/10.1016/j.gendis.2022.11.020

648

Views

8

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD
Received: 01 September 2022
Published: 29 December 2022
© 2023 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).